How common is brain metastasis with NSCLC when both adrenals are involved?
Brain metastasis occurs in about 15-28% of people with NSCLC at diagnosis. Having adrenal involvement doesn't necessarily increase brain metastasis risk, but it does indicate stage 4 disease where cancer has spread to distant sites.
When both Show Full Answer
How common is brain metastasis with NSCLC when both adrenals are involved?
Brain metastasis occurs in about 15-28% of people with NSCLC at diagnosis. Having adrenal involvement doesn't necessarily increase brain metastasis risk, but it does indicate stage 4 disease where cancer has spread to distant sites.
When both adrenal glands are involved, it's more likely to cause symptoms since neither gland can produce adequate hormones. This can lead to fatigue, back pain, stomach pain, nausea, and weight loss. Is this the beginning of the end?
While metastasis indicates advanced disease, it's not necessarily "the end." Treatment advances have significantly improved outcomes. Some people live only months after adrenal metastasis, while others live for years with proper treatment.
The prognosis depends on several factors:
- Your specific type of NSCLC
- Whether cancer has spread to other organs beyond the adrenals
- Your overall health
- Your treatment response
Staying engaged with your medical team and maintaining hope is important. Research shows that people with strong emotional support and resilience report better quality of life during treatment. Going back on Keytruda after stopping:
Restarting immunotherapy like Keytruda can be an option depending on why it was stopped and how your cancer has responded. Your oncology team will evaluate whether resuming treatment makes sense for your specific situation.
Keep communicating openly with your doctors about symptoms and treatment concerns to ensure you're getting the best personalized care possible.
January 2
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
